TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2751279

Group type: EXPERIMENTAL
Intervention: Intramuscular recombinant alpha interferon (rIFN-2A; 9 million IU given for 5 days)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Topical acyclovir
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Intramuscular recombinant alpha interferon (rIFN-2A)
Number of subjects: 105
Study: 799566

Group type: EXPERIMENTAL
Intervention: Bethanidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall side effects
Number of subjects: 0
Study: 31669298

Group type: EXPERIMENTAL
Intervention: Participation restrictions
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Satisfaction with participation
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Correlation between participation restrictions and satisfaction
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Differences between satisfied and dissatisfied partners
Number of subjects: 54
Study: 31893589

Group type: EXPERIMENTAL
Intervention: Densiron® 68
Number of subjects: 23

Group type: COMPARATOR
Intervention: Oxane® HD
Number of subjects: 23
Study: 27901214

Group type: EXPERIMENTAL
Intervention: Long-term psychodynamic psychotherapy (n=90)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Fluoxetine therapy (n=91)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Combination therapy (n=91)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Long-term psychodynamic psychotherapy
Number of subjects: 272

Group type: COMPARATOR
Intervention: Combination therapy
Number of subjects: 272
Study: 26048346

Group type: EXPERIMENTAL
Intervention: Dynamic weight‐bearing Assessment of Pain (DAP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dynamic weight‐bearing Assessment of Pain (DAP) knee bend scores
Number of subjects: 20
Study: 22591950

Group type: EXPERIMENTAL
Intervention: Modafinil (200mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 20605734

Group type: EXPERIMENTAL
Intervention: Vaccinated (V) group
Number of subjects: 72

Group type: COMPARATOR
Intervention: Non-vaccinated (NV) group
Number of subjects: 72
Study: 19409919

Group type: EXPERIMENTAL
Intervention: Viewing distance at 1m (far targets)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Viewing distance at 0.33m (near targets)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Target complexity (simple vs. complex)
Number of subjects: 47
Study: 17803715

Group type: EXPERIMENTAL
Intervention: 600 micrograms oral misoprostol
Number of subjects: 447

Group type: COMPARATOR
Intervention: Manual vacuum aspiration (MVA)
Number of subjects: 447
Study: 14741670

Group type: COMPARATOR
Intervention: Neutral cue trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Valid cue trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Invalid cue trials
Number of subjects: 0
Study: 11496232

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 525
Study: 9579878

Group type: EXPERIMENTAL
Intervention: Erythrocyte zinc protoporphyrin (ZPP) measurement combined with mean corpuscular volume (MCV) measurement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mean corpuscular volume (MCV) measurement
Number of subjects: 0
Study: 7994788

Group type: EXPERIMENTAL
Intervention: Intravesical instillation of epirubicin
Number of subjects: 53
Study: 2719235

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl 100 mcg
Number of subjects: 55

Group type: COMPARATOR
Intervention: Epidural pethidine 50 mg
Number of subjects: 55
Study: 1015894

Group type: EXPERIMENTAL
Intervention: Payne operation (35 cm of jejunum anastomosed end‐to‐side to 10 cm of ileum)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Scott operation (30 cm of jejunum anatomosed end‐to‐end to 15 cm of ileum with the proximal cut end of ileum vented into the transverse colon)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Scott operation with varying lengths of jejunum and ileum
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Length of jejunum
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Postoperative assessment
Number of subjects: 105
Study: 31577546

Group type: EXPERIMENTAL
Intervention: High-voltage PRF followed by local anesthetics, hyaluronidase, and betamethasone
Number of subjects: 41

Group type: COMPARATOR
Intervention: Epidural adhesiolysis (EA)
Number of subjects: 41
Study: 30691507

Group type: EXPERIMENTAL
Intervention: Medical therapy plus percutaneous coronary intervention (PCI)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Medical therapy plus PCI
Number of subjects: 410
Study: 27746061

Group type: EXPERIMENTAL
Intervention: Riociguat 0.5 mg (up-titrated to a maximum dose of 2.5 mg TID over 10 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 0
Study: 25212766

Group type: EXPERIMENTAL
Intervention: Home Hazard Modification Program (HHMP)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (fall prevention multifactorial programs without HHMP)
Number of subjects: 130
Study: 23478342

Group type: COMPARATOR
Intervention: Transcranial alternating current stimulation (tACS) at 1.0 mA intensity between 2 to 250 Hz
Number of subjects: 20
Study: 21234592

Group type: EXPERIMENTAL
Intervention: 6.4% carbohydrate (CHO) beverage
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PLA) (flavoured water)
Number of subjects: 10
Study: 19861694

Group type: EXPERIMENTAL
Intervention: Characterized chondrocyte implantation
Number of subjects: 67

Group type: COMPARATOR
Intervention: Microfracture
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Postoperative low-load activities (high levels)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Postoperative low-load activities (lack of)
Number of subjects: 67
Study: 16969787

Group type: EXPERIMENTAL
Intervention: Tactile stimulation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Electrical stimulation at acupuncture points LI4 and LI11
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acupoint stimulation
Number of subjects: 12
Study: 16649870

Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral package
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Hypnotic cognitive‐behavioral package
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Hypnotic analgesia suggestion
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 188

Group type: COMPARATOR
Intervention: No‐treatment control
Number of subjects: 188
Study: 14657693

Group type: EXPERIMENTAL
Intervention: Alendronate and calcium
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Calcitriol and calcium
Number of subjects: 117
Study: 10598427

Group type: EXPERIMENTAL
Intervention: Diprifusor TCI (TCI group)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Manually controlled infusion (MI group)
Number of subjects: 160
Study: 8526168

Group type: EXPERIMENTAL
Intervention: Alpare D. pteronyssinus extract, maintenance dose of 10,000‐12,500 BU's
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 1936477

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Combination therapy (Glibenclamide added to Metformin)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Combination therapy (Metformin added to Glibenclamide)
Number of subjects: 72
Study: 6757152

Group type: EXPERIMENTAL
Intervention: 5 mg mepindolol daily
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: 12.5 mg hydrochlorothiazide daily
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: 5 mg mepindolol plus 12.5 mg hydrochlorothiazide daily
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo (during washout period)
Number of subjects: 138
Study: 29540872

Group type: EXPERIMENTAL
Intervention: Conservative exercise therapy with Maitland thoracic manipulation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conservative exercise therapy alone
Number of subjects: 40
Study: 27249161

Group type: EXPERIMENTAL
Intervention: Internet-based stress management intervention (iSMI)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Waitlist control group (WLC)
Number of subjects: 264
Study: 25564779

Group type: EXPERIMENTAL
Intervention: State Entropy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bispectral Index (BIS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sevoflurane/Remifentanil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol/Remifentanil
Number of subjects: 40
Study: 23123376

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 gm at induction followed by 3 oral doses of 500 mg during 24 hours)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (no tranexamic acid)
Number of subjects: 200
Study: 20190623

Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PVP)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 49
Study: 18167405

Group type: EXPERIMENTAL
Intervention: Testosterone undecenoate 80 mg twice daily for 6 months
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Testosterone undecenoate
Number of subjects: 237
Study: 17062431

Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Methylprednisolone (40 mg)
Number of subjects: 38
Study: 12937992

Group type: EXPERIMENTAL
Intervention: 360° retinotomy and macular translocation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fellow eye (control)
Number of subjects: 30
Study: 10633486

Group type: EXPERIMENTAL
Intervention: Oral amphetamine (30 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 9360514

Group type: EXPERIMENTAL
Intervention: Bromocriptine-rebound method (group 1)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Long protocol (group 2)
Number of subjects: 162
Study: 1394754

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.25 mg.kg‐1
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.5 mg.kg‐1
Number of subjects: 14
Study: 3915885

Group type: EXPERIMENTAL
Intervention: Tenoxicam (20 mg, 30 mg, 40 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Piroxicam (equivalent once-daily dosage)
Number of subjects: 0
Study: 28953494

Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 110

Group type: COMPARATOR
Intervention: Ephedrine
Number of subjects: 110
Study: 26027555

Group type: EXPERIMENTAL
Intervention: Isotonic PMS (0.9 % saline in 5 % dextrose and potassium chloride 20 meq/L)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Hypotonic PMS (0.18 % saline in 5 % dextrose and potassium chloride 20 meq/L)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Hypotonic PMS
Number of subjects: 119
Study: 25040947

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate polymer film
Number of subjects: 12

Group type: COMPARATOR
Intervention: Traditional barrier film
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 12
Study: 22318052

Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic cholecystectomy (SILC)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 34
Study: 20156044

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 17822829

Group type: EXPERIMENTAL
Intervention: Dominant hand position during UCC-CPR
Number of subjects: 59

Group type: COMPARATOR
Intervention: Non-dominant hand position during UCC-CPR
Number of subjects: 59
Study: 16162034

Group type: EXPERIMENTAL
Intervention: Peptide vaccination (gp100 antigen)
Number of subjects: 10
Study: 12834650

Group type: EXPERIMENTAL
Intervention: Gamblers Anonymous (GA) attendance
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Number of professional sessions attended during treatment
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Number of GA meetings attended during treatment
Number of subjects: 342

Group type: COMPARATOR
Intervention: Non-GA attendees
Number of subjects: 342
Study: 10565804

Group type: EXPERIMENTAL
Intervention: Monthly 12.5 mg intramuscular injections of fluphenazine decanoate
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Monthly 1.5 mg intramuscular injections of fluphenazine decanoate
Number of subjects: 58
Study: 8560997

Group type: EXPERIMENTAL
Intervention: 12 hours of expectant management
Number of subjects: 205

Group type: COMPARATOR
Intervention: 24 hours of expectant management
Number of subjects: 205
Study: 1844268

Group type: EXPERIMENTAL
Intervention: Beta-carotene 30 mg/day plus retinyl palmitate 25,000 IU/day
Number of subjects: 8129

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 8129
Study: 6760030

Group type: EXPERIMENTAL
Intervention: Acyclovir (3% ophthalmic ointment, 5 times a day for 14 days)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Idoxuridine (0.5% ophthalmic ointment, 5 times a day for 14 days)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 64

Group type: COMPARATOR
Intervention: Idoxuridine
Number of subjects: 64
Study: 31971677

Group type: EXPERIMENTAL
Intervention: 4CMenB vaccination at baseline
Number of subjects: 24269

Group type: COMPARATOR
Intervention: Control group (4CMenB vaccination at 12 months)
Number of subjects: 24269

Group type: EXPERIMENTAL
Intervention: 4CMenB vaccination
Number of subjects: 24269

Group type: EXPERIMENTAL
Intervention: Risk factors for carriage (baseline assessment)
Number of subjects: 24269
Study: 31252655

Group type: EXPERIMENTAL
Intervention: Caffeine 3 mg/kg/b.m. (CAF‐3)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Caffeine 6 mg/kg/b.m. (CAF‐6)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Caffeine 9 mg/kg/b.m. (CAF‐9)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 15
Study: 29757459

Group type: EXPERIMENTAL
Intervention: Individual meaning-centered psychotherapy (IMCP)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Supportive psychotherapy (SP)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 321
Study: 25908532

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (4 g)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control (4 g olive oil)
Number of subjects: 85
Study: 24698990

Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WPI) with 21% naturally occurring GMP
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WPI) with 2% naturally present GMP
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Glycomacropeptide (GMP) isolate
Number of subjects: 22

Group type: COMPARATOR
Intervention: Maltodextrin carbohydrate
Number of subjects: 22
Study: 21084552

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 39

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Risperidone and Olanzapine
Number of subjects: 39
Study: 20668151

Group type: EXPERIMENTAL
Intervention: Individualized simulated learning intervention
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (non-intervention clinics)
Number of subjects: 41
Study: 16899309

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 16113020

Group type: EXPERIMENTAL
Intervention: Foreign-born women
Number of subjects: 382

Group type: COMPARATOR
Intervention: Continental US born women
Number of subjects: 382
Study: 12166584

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (500 microg b.i.d.)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Salmeterol (50 microg b.i.d.)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 15
Study: 10378852

Group type: EXPERIMENTAL
Intervention: Nicardipine infusion (0.7 to 1.4 microg/kg/min)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Nitroglycerin infusion (0.5 to 1 microg/kg/min)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 77
Study: 8710426

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine treatment with a low calorie diet
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (diet only)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine treatment
Number of subjects: 19
Study: 1804863

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 10
Study: 6667628

Group type: EXPERIMENTAL
Intervention: 5 mg bendrofluazide
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1 mg bumetanide
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 40 mg xipamide
Number of subjects: 24
Study: 31587658

Group type: EXPERIMENTAL
Intervention: Transdermal GTN (5 mg)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Sham dressing
Number of subjects: 145
Study: 29525821

Group type: EXPERIMENTAL
Intervention: Atorvastatin (2 loading doses of 80 mg before and 24 hours after PCI)
Number of subjects: 4191

Group type: COMPARATOR
Intervention: Placebo (matching placebo before and 24 hours after PCI)
Number of subjects: 4191
Study: 30640985

Group type: EXPERIMENTAL
Intervention: Xingfeng Capsule (XFC), 3 pills each time, three times per day for 3 months
Number of subjects: 76

Group type: COMPARATOR
Intervention: Leflunomide (LEF), 10 mg each time, once per day for 3 months
Number of subjects: 76
Study: 23836484

Group type: EXPERIMENTAL
Intervention: Fused Deposition Modelling (FDM) orthosis
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Selective Laser Sintering (SLS) orthosis
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard Foot Orthosis (SFO)
Number of subjects: 15
Study: 22258265

Group type: EXPERIMENTAL
Intervention: Vitamin D (100,000 IU cholecalciferol given every 2 months) and calcium (1 g/d)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Vitamin D and calcium supplementation
Number of subjects: 59
Study: 20073463

Group type: EXPERIMENTAL
Intervention: Berry group (160 g/day of bilberries, lingonberries, black currants, and chokeberries)
Number of subjects: 72
Study: 17623077

Group type: EXPERIMENTAL
Intervention: Induction of labour
Number of subjects: 325

Group type: COMPARATOR
Intervention: Expectant management with maternal and fetal monitoring
Number of subjects: 325
Study: 16226521

Group type: EXPERIMENTAL
Intervention: Intravitreal injections of 4 mg triamcinolone acetonide (TA)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Macular laser grid photocoagulation (MLG)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 4 mg TA followed by MLG
Number of subjects: 56
Study: 12107236

Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg, orally, three times daily)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Acipimox
Number of subjects: 7
Study: 11772142

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg/day or 10 mg twice daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Rabeprazole
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Rabeprazole 20 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Rabeprazole plus clarithromycin and amoxicillin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 to 40 mg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Rabeprazole 10 to 40 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Rabeprazole 60 to 120 mg/day
Number of subjects: 16
Study: 9698638

Group type: EXPERIMENTAL
Intervention: Symptom specific subscales from the Multiscore Depression Inventory
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (8 women without symptomatic premenstrual change)
Number of subjects: 20
Study: 7735957

Group type: EXPERIMENTAL
Intervention: 1 mg/kg anti-TNF alpha-antibody
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 3 mg/kg anti-TNF alpha-antibody
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison with complete murine monoclonal anti-TNF alpha-antibody
Number of subjects: 20
Study: 2492140

Group type: EXPERIMENTAL
Intervention: Fe(111)‐EDTA fortified masala (curry powder)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-fortified)
Number of subjects: 0
Study: 786416

Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 32
Study: 7376045

Group type: EXPERIMENTAL
Intervention: Highly selective vagotomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Truncal vagotomy and gastroenterostomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both operations
Number of subjects: 40
Study: 30596472

Group type: EXPERIMENTAL
Intervention: Intracavitary electrocardiogram guidance
Number of subjects: 2250

Group type: COMPARATOR
Intervention: Anatomical landmark guidance
Number of subjects: 2250
Study: 30467335

Group type: EXPERIMENTAL
Intervention: CLIFE1 (lidocaine plus diclofenac)
Number of subjects: 120

Group type: COMPARATOR
Intervention: CLIFE2 (lidocaine)
Number of subjects: 120
Study: 26551066

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (Viscoseal) 10 mL intra-articularly
Number of subjects: 48

Group type: COMPARATOR
Intervention: Bupivacaine 10 mL intra-articularly
Number of subjects: 48
Study: 24439974

Group type: EXPERIMENTAL
Intervention: Uninephrectomy (reduction in GFR)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 440
Study: 22484026

Group type: EXPERIMENTAL
Intervention: Vertical infraclavicular approach (n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Coracoid infraclavicular approach (n=30)
Number of subjects: 60
Study: 21490989

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field (PEMF) applied at 1 Hz during canine retraction for 5.0 ± 0.6 months.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no PEMF exposure).
Number of subjects: 10
Study: 17200358

Group type: EXPERIMENTAL
Intervention: Epirubicin 100 mg/m² and Cyclophosphamide 600 mg/m² (EC) every 10 to 11 days for four cycles followed by Paclitaxel 175 mg/m² every 10 to 11 days for four cycles with filgrastim support (300 microg s.c. daily) from day 2 to 24 hours before the next treatment
Number of subjects: 39